<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146468</url>
  </required_header>
  <id_info>
    <org_study_id>RMH 2016.281</org_study_id>
    <nct_id>NCT03146468</nct_id>
  </id_info>
  <brief_title>Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>NIVALLO</acronym>
  <official_title>Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melbourne Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study of the safety and efficacy of nivolumab for the treatment of
      relapsed or residual haematological malignancies after allogeneic stem cell transplantation
      (alloSCT).

      Eligible patients will receive nivolumab at a dose of 3mg/kg intravenously every 2 weeks. The
      primary objective is to evaluate the incidence, severity and treatment responsiveness of GVHD
      following nivolumab treatment post-alloSCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft versus host disease</measure>
    <time_frame>8 weeks</time_frame>
    <description>Cumulative incidence of graft versus host disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft versus host disease</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cumulative incidence of graft versus host disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft versus host disease</measure>
    <time_frame>48 weeks</time_frame>
    <description>Cumulative incidence of graft versus host disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Complete remission and partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>Complete remission and partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Complete remission and partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>48 weeks</time_frame>
    <description>Complete remission and partial remission</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Haematological Malignancy</condition>
  <arm_group>
    <arm_group_label>Nivolumab treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab injection 3mg/kg intravenously every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Injection</intervention_name>
    <description>Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor</description>
    <arm_group_label>Nivolumab treatment arm</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior allogeneic stem cell transplant for a haematological malignancy

          -  Confirmed relapse of haematological malignancy or persistent disease post-alloSCT

          -  Immunosuppression cessation for minimum of 2 weeks

          -  Life expectancy &gt; 2 months

          -  ECOG performance status 0-2

          -  Greater than or equal to 30% CD3+ donor chimerism

          -  Serum creatinine ≤ 1.5 times upper limit of normal OR creatinine clearance ≥ 40mL/min

          -  AST and ALT ≤ 3 times upper limit of normal

          -  Total bilirubin ≤ 1.5 times upper limit of normal (except patients with Gilbert
             Syndrome)

          -  Signed written informed consent

        Exclusion Criteria:

          -  Current evidence of any grade of GVHD

          -  Prior history of grade 2 or higher acute GVHD

          -  Moderate chronic GVHD within the previous 6 months or any prior history of severe
             chronic GVHD

          -  Active, known or suspected autoimmune disease (excluding vitiligo, type 1 diabetes
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to
             recur in the absence of an external trigger)

          -  Positive hepatitis B virus surface antigen

          -  Positive hepatitis C virus antibody

          -  Known human immunodeficiency virus infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ritchie, FRACP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Ritchie, FRACP, PhD</last_name>
    <phone>+61 3 93422520</phone>
    <email>david.ritchie@mh.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Wong, FRACP</last_name>
    <phone>+61 3 93427000</phone>
    <email>eric.wong@mh.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ritchie, FRACP, PhD</last_name>
      <phone>+61 3 93422520</phone>
      <email>david.ritchie@mh.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Eric Wong, FRACP</last_name>
      <phone>+61 3 93427000</phone>
      <email>eric.wong@mh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>David Ritchie, FRACP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Wong, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared by researchers outside of this clinical trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

